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The Effect of Mono(2-ethylhexyl)phthalate
on an Isolated Perfused Rat Heart-Lung
Preparation
by Rosalind S. Labow,* Yvonne A. Barry,* Monika Tocchi,t
and Wilbert J. Keon*
Di(2-ethylhexyl)phthalate (DEHP), the plasticizer used in the biomedical production ofblood storage bags,
hemodialysis systems, cardiopulmonary bypass (CPB) circuitry, and intubation tubes, is extracted from the
plastic material when it comes into contact with biological fluids and is converted to its principal metabolite,
mono(2-ethylhexyl)phthalate (MEHP). We have shown that MEHP causes cardiac and respiratory arrest, as
well as hypotension, when infused into anesthetized rats. Usinga well-ventilated in vitro rat heart-lungprepara-
tion, we investigated the effect of MEHP on pulmonary artery pressure (PAP) and found that MEHP had a
hypertensive effect on the pulmonary vasculature ending in constriction and edema. There was a significant
increase of0.58 mm Hg/min in the PAP ofisolated rat lungs when perfused with MEHP dissolved in Krebs-
Henseleit (K-H) buffer (p = 0.0003). The rat lungs that were perfused with K-H buffer only increased 0.094
mm Hg/min during the same perfusion time of20 min. The watergained duringthistime was 0.22 g/min with
MEHP in the buffer compared to 0.04 g/min with buffer alone. The PO2 in the effluent did not decrease dur-
ingthe perfusion time. The concentration ofMEHP in the rat lungs afterperfusion varied from 20 to 40 ,ug/g.
Although the mechanism ofaction ofMEHP on PAP is too complex to be fully elucidated by this model, the
increase in PAP which we have demonstrated is significant and adds yet another toxic effect of this major
metabolite of the ubiquitous plasticizer, DEHP.
Introduction
Di(2-etylhexyl)phthalate (DEHP) has been the most com-
monly used phthalate ester plasticizer in the manufacture
of polyvinylchloride-derived plastics, especially in the bio-
medical production ofblood storage bags, hemodialysis sys-
tems, cardiopulmonary bypass (CPB) circuitry, and the tubes
used forintubation ofpatients requiringrespiratory assistance
(1). DEHP is extracted from the plastic material when it
comes into contact with lipophilic biological fluids, especially
blood, and is converted to its principal metabolite,
mono(2-ethylhexyl)phthalate (MEHP) (2).
It has been known for some time that phthalic acid ester
and trimellitic anhydride (TMA) plasticizers have caused a
spectrum ofrespiratory symptoms in workers in the plastics
industry. The symptoms forTMAhave ranged from asthma-
rhinitis syndrome ofboth delayed and immediate onset (3,4)
to acute pulmonary hemorrhage and edema (5). Ahmad et
al. (6) reported that seven workers exposed to TMA
developed hemolytic anemia and repeated hemoptyses.
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Earlier, DEHP had been reported to have caused the forma-
tion ofmicroemboli, impedingpulmonary bloodflow and pos-
sibly producing death via the shock lung syndrome that is
seen following massive blood transfusions (7). This is sup-
ported by reports ofpulmonary insufficiency and edema in
humans followingbloodtransfusions (8,9). Autian (16) report-
ed that when mice were given 14C-DEHP IV for 7 days,
the lungs contained the highest specific activity ofany organ
studied. Recently, ithas been reported that DEHP accumu-
lated in the lungs ofneonates requiringintubation for a num-
ber ofrespiratory problems, and it has been suggested that
the high levels of DEHP measured may have contributed
to the death of these neonates (1).
Substantial evidence has shown that the toxic effects
observed in animals are due not to DEHP, but to MEHP,
andinclude testicular atrophy (11), fetotoxicity/teratogenicity
(12), and carcinogenicity (13,14). In addition, we have shown
aninhibitory effectofMEHP, butnotofDEHP, onthe human
platelet enzyme phospholipase A2 (15). MEHP also causes
cardiac and respiratory arrest, as well as hypotension, in
anesthetized rats (16). After showing that both DEHP and
MEHP accumulated in the blood ofpatients undergoing CPB
operations for avariety ofreasons (17), we established that
a dose-dependent cardiodepressive effect ofMEHP, butnot
DEHP, occurs inisolated human atrial (18) andpapillary (19)
muscle preparations.LABOW ET AL.
In order to study the respiratory effects of MEHP, we
used a well-ventilated in vitro rat heart-lung preparation and
perfused the lungs with Krebs-Henseleit buffer containing
MEHP. The rate of change of pulmonary artery pressure
(PAP) with MEHP was compared to a control group per-
fused with buffer only. The extent of the accumulation of
water and MEHP in the lungs during this time was also
measured.
Experimental Procedure
In Vitro Rat Heart-Lung Prepamtion
The rats (Sprague-Dawley, males, 250 g, Charles River,
Ontario) were anesthetized with Somnotol (MTC Pharma-
ceuticals, Canada Packers, Cambridge, Ontario) (70 mg/kg),
placed on their backs, and their limbs were taped down.
An incision was made cranial from the external genitalia to
the tip ofthejaw. The strap muscles in the neck area were
blunt dissected and the trachea exposed. A cut between
two rings ofthe trachea, just caudal to the cricoid cartilage,
was made, and apolyethylene cannula (0.055 inches ID) was
inserted and secured with a 0.0 suture. The cannula was
connected via silastic tubing to a Harvard RodentVentilator,
model 683 (Eaiing Scientific, St. Laurent, Quebec). The rat
wasventilatedatarateof50/minwithatidalvolumeof2.5cc.
Next, the abdominal wall was cut from the level of the
penis to the xiphoid process, and the viscera were placed
offcenter to expose the inferior vena cava. A mixture of0A5
cc ofheparin (1000 IU/mL, equivalent to 100 IU/100 gbody
weight) and 0.15 cc of a modified Krebs-Henseleit (K-H)
buffer (composition is described below) was injected into
the inferior vena cava. The diaphragm was cut, the chest
opened, the ribs spread apart and the thymus removed.
The rat was then exsanguinated by cutting the inferiorvena
cava. A small incision was made in the right ventricle, and
a polyethylene cannula (0.055 inches ID) was inserted into
the pulmonary artery (PA). This cannula was secured with
a2.0 suture. The apex ofthe heartwas cut offandthe mitral
valve pierced to ensure easy outflow of the perfusate.
The lungs and nonfunctioning heart were then excised,
and to preventthe entry ofany airbubble into the pulmonary
vasculature, the cannula wastopped offwithK-H bufferusing
a needle. The organs were immediately weighed and then
attached to the in vitro circuit (Fig. 1). The circuit consisted
ofa waterheater and pump (Techne TempetteJuniorTE-8J,
Mandel Scientific, Montreal, Quebec) which circulated water
from a bath into the external compartment of a heating coil
to keep the perfusate atphysiological temperature. The per-
fusate, which was kept in the water bath, was pumped by
a Gilson Minipulse 2 peristaltic pump (Mandel Scientific,
Montreal, Quebec) into the internal compartment of the
heating coil. From there the perfusate entered the PA can-
nula and the lungs with an initial flow rate of 3.4 mL/ min.
Just at the junction of the PA cannula and the heating coil,
a T-junction provided for lateral pressure measurement of
the PAP via a Statham Gould pressure transducer (Allen
Crawford Associates, Ottawa, Ontario). The pressure was
then recorded on a Grass 79D oscillograph (Grass Instru-
ments, Quincy, MA). The cannula was initially adjusted so
as to read a minimum pressure and from there, the flow
rate was modified to one which yielded a stable pressure
close to 5 mmHg. After a period ofstabilization ofapproxi-
mately 5 min, the perfusate was changedfrom the K-H con-
trol to K-H containing varying amounts ofMEHP. Samples
ofthe perfusate and the effluent were taken at 5-min inter-
vals throughout each experiment for determination ofPO2,
using a pH/ blood gas analyzer, model no. 1306, (Fisher
Scientific Ltd., Nepean, Ontario) as well as for extraction
FIGURE 1. The in vitro rat heart-lung circuit. Krebs-Henseleit (K-H) buffer and K-H buffer with MEHP (continuously stirred by a magnetic stirrer) is maintain-
ed at 37°C in a heated water bath. This water is also pumped through a heating coil to maintain the perfusate at 37°C while it is being pumped by the
peristaltic pump at a rate of3A mL/min from the reservoirs to the lungs via the puhmonary artery. The lungs are aerated through the trachea with a mechanical
ventilator at a rate of50/min wvith a tidal volume of2.5 cc. The changes in pulmonary artery pressure are monitored by a pressure transducer and recorded.
The details of the surgical procedure for the preparation of the lungs are described in "Experimental Procedure."
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of MEHP for analysis by HPLC in order to determine the
exact concentration. At the end ofthe experiment, the lungs
were reweighed to permitthe calculation ofthe watergained
and then frozen for later MEHP extraction.
Preparation of the Perfusate
The modified K-H buffer was prepared with the follow-
ing composition (millimolar): NaCl, 109; KCl, 4.7; MgSO4,
1.2; NaH2PO4, 1.2; NaHCO3, 25; CaCl2, 2.5; glucose, 11;
fumaric acid, 5; glutamic acid, 5; sodium lactate, 5; zinc
insulin 25 mU/mL; and amino acids andvitamins as in Eagles
medium (20). Human serum albumin obtained from the
Canadian Red Cross was added to give a final concentra-
tion of 5%. The final pH was adjusted to 7.4 with sodium
hydroxide (1ON).
MEHP (Fairfield Chemical Co., Inc., Blythewood, SC)
was dissolved in 0.15 M NaHCO3 at a concentration of 10
mg/mL and added to the K-Hbufferin amountsvaryingfrom
15 to 150 /tg/mL just before the perfusion was started.
Analysis of Rat Lungs and Perfusates
for MEHP
Specimens of 100 mg from the rat lung preparation were
extracted for accumulation of MEHP. Extraction of the
tissues was done according to the procedure ofAcott et al.
(21), using a ground glass homogenizer and sodium sulfate
to break up the tissue. HPLC, model no. 5000 (Varian
Associates, Georgetown, Ontario) was used to determine
the concentration of MEHP (22) in the extracted lungs as
well as in aliquots of the perfusates and effluents.
Table 1. Effect of perfusion of buffer and MEHP on rat lungs.
MEHP, Time with
jLg/mL MEHP, min
0 0
0 0
0 0
0 0
0 0
0 0
0 0
0 0
Mean
15.6 12.50
16.6 7.50
25.7 17.50
31.82 18.50
32.2 10.50
34.8 22.25
39.3 14.00
44.48 10.75
48.7 14.00
56.8 10.50
58.0 7.75
59.8 8.00
60.77 16.50
61.6 12.50
66.23 24.00
68.25 23.25
87.43 13.50
90.29 15.25
91.76 15.50
107.3 27.25
112.2 17.75
120 13.00
150 22.00
Mean
Total time Rate of pressure
perfused, change,
min mm Hg/min
31.00 0.153
21.00 0.024
27.75 0.180
14.50 0.035
15.00 0.017
19.00 0.092
20.00 0.088
21.75 0.161
21.25 (2.02)a 0.094 (0.023)
18.00 0.68
14.00 0.800
21.75 0.114
25.00 0.135
16.00 1.095
27.75 0.225
21.25 0.286
16.25 0.837
18.00 0.143
18.75 0.500
13.50 1.806
13.50 0.688
21.50 0.652
18.25 1.000
28.00 0.208
29.75 0.366
20.00 0.815
22.50 0.705
20.75 0.726
33.75 0.303
23.00 0.648
18.00 0.308
27.00 0.324
21.5 (1.12) 0.58 (0.08)
a Standard error of the mean in parentheses.
Electron Microscopy of Perfused Rat Lungs
The lungs were inflated with and immersed in 2.5% glu-
taraldehyde. A biopsy of the upper segment of each of the
lower lobes ofeach ofthe rats was taken after fixation. They
were examined morphologically, with the observer blinded
as to whether individual specimens were MEHP exposed
or controls. The tissue was then washed in cacodylate buffer
and osmicated in 1% osmium tetroxide in 0.1 M sodium
cacodylate with 1% potassium ferricyanide. The tissue was
en bloc stained with saturated aqueous uranyl acetate and
blocked in Epon-Araldite. The blocks were sectioned with
a glass blade and thick 1-ntm sections prepared, stained with
methylene blue, and examined by light microscopy. Thin 5
to 600 A sections were prepared with an ultramicrotome
and diamond knife, stained with lead citrate, and examined
on a Philips 301 electron microscope.
Results
When the lungs were perfused with K-H buffer alone,
there was a very small change in the increase in PAP during
the perfusion time. The maximum time of perfusion was
close to 20 min, after which time the edema became too
great and the perfusion rate decreased with a very sharp
increase in PAP. During the 20-min period, the rate ofwater
gain was < 0.1 g/min, which was acceptable for this type
of preparation (23) (Table 1).
The range of values obtained with controls for both in-
crease in PAP and watergain are presented inTable 1. When
MEHP was dissolved in the K-H buffer and perfused through
the lung preparation, there was a rise in the rate ofincrease
of PAP (mm Hg/min) during the 20-min perfusion period
along with a greater increase in water gain (Table 1). The
values for MEHP concentration in the perfusate ranged from
15 to 150 ug/mL. Both the increase in PAP and water gain
showed a poor correlation overall with the increase in the
concentration of MEHP or time of perfusion with MEHP.
There was considerable variability in the response ofeach
animal (r = 0.55 andp = 0.0023 for MEHP and PAP). How-
ever, when the group ofexperimental lungs were analyzed
as a whole, there was a significant effect on the PAP (p =
0.0003) if MEHP was present in the K-H perfusate when
compared with the controls when only K-H buffer was per-
fused (rank sum test of presence of MEHP versus rate).
The rate of increase was 0.58 + 0.08 mm Hg/min with
MEHP and only 0.094 + 0.023 mm Hg/min withbuffer alone
(Table 1). There was also a large difference (5-fold) in the
amount of edema in the experimental lungs, 0.22 + 0.02
g/min increase in weight (Table 1) when compared to the
Weight gain,
g/min
0.022
0.046
0.017
0.020
0.075
0.045
0.066
0.031
0.04 (0.008)
0.213
0.192
0.229
0.003
0.228
0.350
0.100
0.317
0.517
0.167
0.426
0.312
0.173
0.333
0.125
0.121
0.174
0.217
0.197
0.158
0.275
0.069
0.120
0.22 (0.02)
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Table 2. Gas analyses of rat-lung perfusate.
P02, mm Hg
Group Start End
Control 180 141
Control 134 121
Experimental 152 145
Experimental 139 135
Experimental 139 117
Experimental 139 114
controls when the rate of water accumulation was only
0.04 ± 0.008 g/min during the perfusion period.
Both the experimental and control lung preparations were
well aerated during the perfusion period since the PO2
measured in the effluent did not change significantly from
the beginning to the end of the perfusion time (Table 2).
When the rat lungs were extracted and analyzed for MEHP,
there was an accumulation ofMEHP inthe tissue thatvaried
from 20 to 40 ,ug/g. However, this was always lower than
the concentration of MEHP in the perfusate. The histo-
pathologic examination ofthe lung preparations showed no
discernible differences at the light or ultrastructural levels
when the MEHP-exposed and control tissues were
compared.
Discussion
We had observed that MEHP caused cardiac and respira-
tory arrest when infused into anesthetized rats when we
were monitoring heart rate andblood pressure, both ofwhich
were depressed (16). In an intact, anesthetized animal, many
factors can contribute to the pathogenesis of the cardio-
depressive effect. We had already shown the cardiodepres-
sive effects in isolated human atrial trabecular muscle prep-
arations (18,19). Therefore, in order to isolate the effects of
MEHP to the respiratory system, we developed an in vitro
rat heart-lung preparation where the heart is nonfunctional
andthe lungs are well aerated mechanically. Ourresults have
shown a significant effect on PAP when MEHP is present
in K-H perfusate (p = 0.0003).
The lack of a good correlation (r = 0.55) between increas-
ing concentrations of MEHP and PAP and water gain and
the high variability in the response from animal to animal
was probably due to MEHP having more than one effect
on the lungs as well as the direct effect ofperfusion on water
gain in this preparation which is not related to MEHP (23).
The effects of MEHP on the increase of PAP and water
gain are related, but probably are two different phenomena
which have different mechanisms. This may be part of the
reason for the lack ofgood correlation between MEHP con-
centration and the increase in PAP. The biological variability
in the two responses of the pulmonary artery to MEHP,
i.e., water gain and increased pressure, may be more than
additive. Certainly, water gain alone will also cause an in-
crease in PAP (23,24). In addition, the variation in the perfu-
sion times with and without MEHP make correlation to one
variable very difficult. Perhaps the lack of a dose response
indicates thatthere are differentthresholds for an all-or-none
phenomenon for both the hypertensive and water gain
effects.
There are several possible mechanisms by which MEHP
may exert its effects on PAP and water gain in this prepara-
tion. When considering the 6-fold increase in the PAP, it
is important to note that the lung is affected by changes in
hydrostatic and oncotic pressures as well as ventilation or
ischemia. All ofthese factors are determinedby interactions
ofthe pulmonary cellular components ofthe vasculature and
the fluid flowing past them. Although the smooth muscle
cells are important in maintaining the tonicity ofthe vessel
wall, it is the endothelial cell that is important in controlling
PAP by altering the vasoactivity by the following mech-
anisms: a) control ofrelease ofvasoactive substances that
influence vascular tone at the site of or at a site distal to
that ofits formation/alteration/uptake (24); b) regulation of
smooth muscle tonicitythrough the formation ofamediator;
and c) control of viscosity of the fluid by interacting at the
endothelial cell surface (25).
For example, vasodilatory substances to the endothelium,
such as acetylcholine, bradykinin, and serotonin can become
vasoconstrictive when introduced to denuded pulmonary
vessels (26). Ischemia/hypoxia also causes a hypotensive
factor to be released from endothelial cellwails (endothelium-
derived relaxing factor [EDRF]) (27). MEHP may be exert-
ing its action by interfering with one or more of the three
mechanisms descnbed above, by damaging the endothelium,
which then reverses the relaxation effects of EDRF to a
contraction (26). However, there have been several studies
that suggest that MEHP acts through the cholinergic system.
These include the inhibition of acetylcholine-induced rat
gastric muscle contraction (28), as well as our own studies
which demonstrated that the cardiodepressive effect of
MEHP inthe atrial human in vitro muscle preparation could
be blocked by atropine (19). Pfuderer et al. (29) showed
that atropine also blocked the heart depressor effects of
several phthalate esters in the goldfish. Since the rat lung
preparation described in this study is well-ventilated, the
increase in PAP caused by MEHP is consistent with a
cholinergic effect, as acetylcholine can be vasoconstrictive
ifpulmonary vessels are damaged and ifthere is no hypoxia
(26,27).
The 5-fold increase in water gained during the perfusion
periodindicated that there was an alteration in the pulmonary
vasculature caused by MEHP, although no morphological
changes were apparentotherthan edema, which was evident
in both the control and MEHP-perfused lungs. It appears
thatthe permeability ofthe pulmonary vasculature may have
beenalteredwithoutvisible ultrastructuralchanges occuring.
Edema is caused by changes in the capillary and tissue
hydrostatic and oncotic pressures regulatingthe transcapilary
gradient as describedbytheStarlinghypothesis. Anyminimal
change in either the hydrostatic pressure (such as an in-
crease) withinthe capillary or a decrease in its oncotic pres-
sure will lead to increased fluid leakage out ofthe capillary
into the interstitium, resulting in edema. In this prepara-
tion, maximal effort was placed in maintaining a physiological
intracapillary hydrostatic as well as oncotic pressure. How-
ever, it is difficult to control interstitial and intracellular
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hydrostatic and oncotic pressures in these ex vivo prepara-
tions. Others (23,24) have had simnilar problems. Nonethe-
less, itis apparent that more thanjust the in vitro artifactual
edema was present in the experimental lungs since there
was a significant increase in the water gained per minute
when MEHP was present. It is possible that the edema
observed was the result ofan effect ofMEHP on the endo-
thelial cell and its functions, since other biologically active
substances such as prostaglandins can do the same by
increasing the endothelial celljunctional gaps, allowing water
to leak out (30). Although this is only ahypothetical explan-
ation, it should be explored further.
It is evident, however, that the mechanism of action of
MEHP on the pulmonary artery is too complex to be fully
elucidated by this model. Nonetheless, the increase in PAP
and edema that we have demonstrated by using MEHP is
significant and adds yet another toxic effect of this major
metabolite of the ubiquitous plasticizer, DEHP.
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